| Ytd | -77.61% | |
| 1y | -85.29% |
| Open | 0.34 | Prev Close | 0.35 | Low | 0.33 | High | 0.36 | Mkt Cap | 3.51M |
| Vol | 122.26K | Avg Vol | 753.05K | EPS | -0.74 | P/E | N/A | Forward P/E | 116.50 |
| Beta | 0.78 | Short Ratio | 0.41 | Inst. Own | 2.95% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-10 | 50-d Avg | 0.45 | 200-d Avg | 0.95 | 1yr Est | 6.00 |
NXGL News
Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 35.9% to $7.3 during Tuesday's
Planet Green Holdings Corp (NYSE: PLAG) saw a sharp increase in pre-market trading after Curvature S
Major M&A deals include: T Rowe Price buys F/M Investments, ScanSource acquires CleanWater1, Bar
Gainers Werewolf Therapeutics (NASDAQ:HOWL) shares increased by 108.1% to $0.9 during Friday's
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL") today announced a
LANGHORNE, Pa. , Aug. 20, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ:
Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 108.9% to $2.03 during Monday's reg
US stocks mixed, S&P 500 drops 0.2%. Dow down 0.34%, NASDAQ up 0.04%. Industrials up 0.2%, consu
US stocks mixed, Dow falls 150 points. Dow down 0.31%, NASDAQ up 0.03%, S&P 500 down 0.12%. Tech
NexGel (NASDAQ:NXGL) reported quarterly losses of $(0.40) per share which missed the analyst consens
LANGHORNE, Pa., Aug. 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ:
Gainers Mereo BioPharma Group (NASDAQ:MREO) stock increased by 21.7% to $0.33 during Tuesday's
Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-m
LANGHORNE, Pa. , June 04, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ:
The study concluded that NEXGEL's hydrogel patch significantly reduced laser plume generation an
The study concluded that NEXGEL's hydrogel patch significantly reduced laser plume generation and ex
NEXGEL, Inc. (NXGL) Q1 2026 Earnings Call Transcript
NexGel (NASDAQ:NXGL) reported quarterly losses of $(0.11) per share which missed the analyst consens
Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Tra
Management Will Host a Conference Call at 12:00 P. M. ET on the Same Day LANGHORNE, Pa. , May 12, 20
Sequence LifeScience TM Led Financing to Close on Acquisition of Celularity with Strategic Investmen
Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Busines
NexGel (NASDAQ: NXGL) used a shareholder update conference call to discuss the closing of its acquis
NEXGEL, Inc. (NXGL) Q4 2025 Earnings Call Transcript
Transaction expected to approximately triple NEXGEL's annual revenue to approximately $35 million an
NexGel (NASDAQ: NXGL - Get Free Report) and Pressure BioSciences (OTCMKTS:PBIO - Get Free Report) ar
LANGHORNE, Pa., April 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ:
LANGHORNE, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ:
LANGHORNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ:
NexGel (NASDAQ:NXGL) reported quarterly losses of $(0.12) per share which missed the analyst consens
LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ:
NexGel (NASDAQ: NXGL - Get Free Report) is expected to be releasing its Q4 2025 results after the ma
Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is
Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an ad
NexGel to acquire Celularity biomaterial products, a deal expected to triple revenue to $35 million
ZVRA up in pre-market trading on better-than-expected Q4 results. Gainers include BRTX, COOT, BIYA,
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provide